Supernus Announces Fourth Quarter and Full Year 2024 Financial Results
Supernus Pharmaceuticals (SUPN) reported strong financial results for Q4 and full year 2024, with total revenues increasing 9% to $661.8 million. Qelbree showed exceptional growth with Q4 net sales up 60% to $74.4 million and full-year sales up 72% to $241.3 million. GOCOVRI sales also improved, rising 15% in Q4 to $36.9 million.
The company achieved full-year 2024 operating earnings of $81.7 million, compared to a loss in 2023. Notable developments include FDA approval of ONAPGO for Parkinson's disease, planned for launch in Q2 2025, and a patent extension for Qelbree until 2035.
For 2025, Supernus projects total revenues between $600-630 million and adjusted operating earnings of $105-130 million. The company maintains a strong financial position with $453.6 million in cash and marketable securities as of December 31, 2024.
Supernus Pharmaceuticals (SUPN) ha riportato risultati finanziari solidi per il quarto trimestre e per l'intero anno 2024, con ricavi totali in aumento del 9% a $661,8 milioni. Qelbree ha mostrato una crescita eccezionale, con le vendite nette del quarto trimestre in aumento del 60% a $74,4 milioni e le vendite annuali in aumento del 72% a $241,3 milioni. Anche le vendite di GOCOVRI sono migliorate, aumentando del 15% nel quarto trimestre a $36,9 milioni.
L'azienda ha raggiunto un utile operativo per l'intero anno 2024 di $81,7 milioni, rispetto a una perdita nel 2023. Sviluppi notevoli includono l'approvazione della FDA per ONAPGO per il morbo di Parkinson, prevista per il lancio nel secondo trimestre del 2025, e un'estensione del brevetto per Qelbree fino al 2035.
Per il 2025, Supernus prevede ricavi totali tra $600-630 milioni e utili operativi rettificati di $105-130 milioni. L'azienda mantiene una posizione finanziaria solida con $453,6 milioni in contante e titoli negoziabili al 31 dicembre 2024.
Supernus Pharmaceuticals (SUPN) reportó resultados financieros sólidos para el cuarto trimestre y para todo el año 2024, con ingresos totales que aumentaron un 9% a $661.8 millones. Qelbree mostró un crecimiento excepcional con ventas netas en el cuarto trimestre que aumentaron un 60% a $74.4 millones y ventas anuales que aumentaron un 72% a $241.3 millones. Las ventas de GOCOVRI también mejoraron, aumentando un 15% en el cuarto trimestre a $36.9 millones.
La compañía logró ganancias operativas de $81.7 millones para todo el año 2024, en comparación con una pérdida en 2023. Los desarrollos notables incluyen la aprobación de la FDA para ONAPGO para la enfermedad de Parkinson, programada para su lanzamiento en el segundo trimestre de 2025, y una extensión de la patente para Qelbree hasta 2035.
Para 2025, Supernus proyecta ingresos totales entre $600-630 millones y ganancias operativas ajustadas de $105-130 millones. La compañía mantiene una sólida posición financiera con $453.6 millones en efectivo y valores negociables al 31 de diciembre de 2024.
Supernus Pharmaceuticals (SUPN)는 2024년 4분기 및 전체 연도에 대한 강력한 재무 결과를 보고했으며, 총 수익이 9% 증가하여 6억 6,180만 달러에 달했습니다. Qelbree는 4분기 순매출이 60% 증가하여 7,440만 달러에 이르고, 연간 매출은 72% 증가하여 2억 4,130만 달러에 달하는 뛰어난 성장을 보였습니다. GOCOVRI의 매출도 개선되어 4분기 15% 증가하여 3,690만 달러에 도달했습니다.
회사는 2024년 전체 연도 운영 수익이 8,170만 달러에 달하며, 2023년에는 손실을 기록했습니다. 주목할 만한 발전으로는 파킨슨병 치료를 위한 ONAPGO의 FDA 승인과 2025년 2분기 출시 예정, 그리고 Qelbree의 특허 연장이 2035년까지 이루어지는 것입니다.
2025년을 위해 Supernus는 총 수익을 6억 ~ 6억 3천만 달러로 예상하고, 조정된 운영 수익은 1억 5천만 ~ 1억 3천만 달러로 예상합니다. 회사는 2024년 12월 31일 기준으로 4억 5,360만 달러의 현금 및 유가 증권을 보유하여 강력한 재무 상태를 유지하고 있습니다.
Supernus Pharmaceuticals (SUPN) a annoncé de solides résultats financiers pour le quatrième trimestre et l'année entière 2024, avec des revenus totaux en hausse de 9 % à 661,8 millions de dollars. Qelbree a connu une croissance exceptionnelle, avec des ventes nettes au quatrième trimestre en hausse de 60 % à 74,4 millions de dollars et des ventes annuelles en hausse de 72 % à 241,3 millions de dollars. Les ventes de GOCOVRI ont également progressé, augmentant de 15 % au quatrième trimestre à 36,9 millions de dollars.
L'entreprise a réalisé un bénéfice d'exploitation pour l'année 2024 de 81,7 millions de dollars, contre une perte en 2023. Parmi les développements notables, on trouve l'approbation de la FDA pour ONAPGO dans la maladie de Parkinson, prévue pour lancement au deuxième trimestre 2025, et une extension de brevet pour Qelbree jusqu'en 2035.
Pour 2025, Supernus projette des revenus totaux compris entre 600 et 630 millions de dollars et un bénéfice d'exploitation ajusté de 105 à 130 millions de dollars. L'entreprise maintient une solide position financière avec 453,6 millions de dollars en liquidités et titres négociables au 31 décembre 2024.
Supernus Pharmaceuticals (SUPN) hat starke finanzielle Ergebnisse für das vierte Quartal und das Gesamtjahr 2024 berichtet, mit einem Anstieg der Gesamterlöse um 9% auf 661,8 Millionen Dollar. Qelbree verzeichnete ein außergewöhnliches Wachstum, wobei die Nettoumsätze im vierten Quartal um 60% auf 74,4 Millionen Dollar stiegen und die Umsätze für das gesamte Jahr um 72% auf 241,3 Millionen Dollar zunahmen. Auch die Verkäufe von GOCOVRI verbesserten sich und stiegen im vierten Quartal um 15% auf 36,9 Millionen Dollar.
Das Unternehmen erzielte für das gesamte Jahr 2024 einen operativen Gewinn von 81,7 Millionen Dollar, verglichen mit einem Verlust im Jahr 2023. Bemerkenswerte Entwicklungen umfassen die FDA-Zulassung von ONAPGO für die Parkinson-Krankheit, die für das zweite Quartal 2025 geplant ist, sowie eine Verlängerung des Patents für Qelbree bis 2035.
Für 2025 prognostiziert Supernus Gesamterlöse zwischen 600 und 630 Millionen Dollar sowie bereinigte Betriebsergebnisse von 105 bis 130 Millionen Dollar. Das Unternehmen bleibt mit 453,6 Millionen Dollar in Bargeld und marktfähigen Wertpapieren zum 31. Dezember 2024 in einer starken finanziellen Position.
- Q4 Qelbree sales up 60% to $74.4M
- Full year revenue increased 9% to $661.8M
- Operating earnings improved from -$5.3M to $81.7M
- FDA approval of ONAPGO for Parkinson's disease
- Qelbree patent extended to 2035
- Cash position strengthened to $453.6M
- Projected revenue decline for 2025 ($600-630M vs $661.8M)
- Expected operating loss up to $15M in 2025
- Declining sales of Trokendi XR and Oxtellar XR due to generic erosion
- SPN-820 failed to meet primary endpoints in Phase 2b depression trial
Insights
Supernus Pharmaceuticals delivered strong financial results for Q4 and full-year 2024, highlighted by exceptional growth in its core products while navigating the expected decline in its legacy epilepsy franchise. The company reported
The growth story centers on Qelbree, Supernus's non-stimulant ADHD medication, which saw
GOCOVRI for Parkinson's disease also showed solid traction with
The pipeline delivered mixed results: SPN-817 for epilepsy showed promising Phase 2a efficacy in treatment-resistant focal seizures and has advanced to Phase 2b, while SPN-820 for treatment-resistant depression failed to meet its primary endpoints in Phase 2b. This setback narrows the late-stage pipeline but allows for resource reallocation to commercial products and remaining candidates.
Despite the strong 2024 performance, Supernus's 2025 guidance of
Supernus has strengthened its financial position with
While 2025 presents challenges from generic erosion, Supernus appears well-positioned with Qelbree's continued growth trajectory, ONAPGO's launch potential, and financial resources to weather this transition period as it evolves into a CNS-focused growth company less dependent on its legacy products.
- Fourth quarter 2024 net sales of Qelbree® increased
60% to$74.4 million , compared to the same period in 2023. Full year 2024 net sales of Qelbree increased72% to$241.3 million , compared to full year 2023. - Fourth quarter 2024 net sales of GOCOVRI® increased
15% to$36.9 million , compared to the same period in 2023. Full year net sales of GOCOVRI increased9% to$130.8 million , compared to full year 2023. - Full year 2024 revenues increased
9% to$661.8 million , compared to the same period in 2023; Full year 2024 total revenues excluding Trokendi XR and Oxtellar XR net product sales (non-GAAP)(1) increased25% , compared to full year of 2023. - Full year 2024 operating earnings of
$81.7 million , compared to operating loss of$(5.3) million in 2023; Full year 2024 adjusted operating earnings (non-GAAP)(1) increased47% to$183.7 million , compared to full year 2023.
- ONAPGO™ (apomorphine hydrochloride), formerly known as SPN-830, approved by the U.S. Food and Drug Administration and will be launched in the second quarter of 2025.
- Full year 2025 guidance for total revenues of
$600 million to$630 million , operating earnings (loss) of$(15) million to$10 million and adjusted operating earnings (Non-GAAP)(1) of$105 million to$130 million .
ROCKVILLE, Md., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for fourth quarter and full year 2024 and associated Company developments.
“Our 2024 results reflect solid commercial execution across the company, including continued growth of our core products, and strong growth in operating earnings,” said Jack Khattar, President and CEO of Supernus. “In 2025, we look forward to continued Qelbree growth; the launch of ONAPGO for the treatment of Parkinson’s disease, planned for the second quarter of 2025; and further advancement of our product pipeline.”
Qelbree Highlights
- The U.S. Food and Drug Administration (FDA) has approved an update for the label for Qelbree to include new pharmacodynamic data. The updated label highlights Qelbree’s partial agonist activity at the serotonin 5-HT2C receptor and inhibition of the norepinephrine transporter, reinforcing its multimodal pharmacodynamic profile. Additionally, the updated label now includes new lactation data for breastfeeding women with attention-deficit/hyperactivity disorder (ADHD), showing that the transfer of Qelbree into breastmilk is low.
- The Company recently presented interim results from an open-label Phase IV trial with Qelbree in 161 adults with ADHD and mood symptoms at the 30th Annual National Psychopharmacology Update™ conference. The improvements in clinician and patient-rated measures of ADHD, depression and anxiety symptoms in the interim data analysis, analyzed for the first 95 patients who completed the trial, are encouraging and suggest that Qelbree's effects may extend to adults with complex ADHD. Efficacy and safety outcomes were consistent with the double-blind, pivotal trial of Qelbree in adult ADHD. Topline results from the full Phase IV trial (all 161 adults) are consistent with the interim results and will be presented at the American Psychiatric Association Annual Meeting in May 2025.
- Total IQVIA prescriptions(2) for Qelbree were 214,613 and 767,791 for the fourth quarter and full year of 2024, respectively, an increase of
25% for both periods compared to the same periods in the prior year. - The Company received a two-plus year patent term extension from the US Patent and Trademark Office for US Patent number 9,662,338 that covers Qelbree. This extends the original expiration date of the patent to the year 2035.
Product Pipeline Update
ONAPGO (formerly, SPN-830) (apomorphine infusion device) for treatment of Parkinson's disease (PD)
- The Company announced in early February 2025 that the FDA approved ONAPGO (apomorphine hydrochloride), formerly known as SPN-830, as the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced PD. The Company plans to launch ONAPGO in the second quarter of 2025 with a support team of experts, including a robust nurse education program, and access support.
SPN-817 – Novel first-in-class highly selective AChE inhibitor for epilepsy
- In November 2024, the Company reported topline results from an open label Phase 2a study in patients with treatment-resistant seizures. The study suggested a differentiated profile, with strong efficacy in focal seizures at the 3mg to 4mg twice daily doses. SPN-817 was safe and had acceptable tolerability with two subjects discontinuing because of treatment related adverse events out of the 26 subjects who entered the maintenance period.
- The Company has initiated a Phase 2b randomized, double-blind, placebo-controlled study of 3mg and 4mg twice daily doses with a targeted enrollment of approximately 258 adult patients with treatment resistant focal seizures.
SPN-820 – Novel first-in-class molecule that increases mTORC1 mediated synaptic function for depression
- In February 2025, the Company reported topline results from a randomized double-blind placebo-controlled Phase 2b study of SPN-820 in adults with treatment-resistant depression (TRD). The study did not demonstrate a statistically significant improvement on the primary and secondary endpoints. The safety profile of SPN-820 was consistent with previous clinical trials, showing few adverse events. The Company will continue to analyze the data and decide on the future of the program.
SPN-443 – Novel stimulant for ADHD/CNS
- Supernus completed a Phase 1 pharmacokinetic study of two oral formulations in healthy adults. Both formulations of SPN-443 showed adequate bioavailability and were well tolerated.
Financial Highlights
This section includes information on non-GAAP financial measures. See “Non-GAAP Financial Information” section for information on non-GAAP financial measures. In addition, a reconciliation of applicable GAAP to non-GAAP financial information is included at the end of this press release.
Revenues
The following table provides information regarding total revenues (dollars in millions):
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||
| 2024 | 2023 | Change % | 2024 | 2023 | Change % | ||||||||||||
| Net product sales | |||||||||||||||||
| Qelbree | $ | 74.4 | $ | 46.4 | $ | 241.3 | $ | 140.2 | |||||||||
| GOCOVRI | 36.9 | 32.0 | 130.8 | 119.6 | |||||||||||||
| Oxtellar XR | 13.2 | 31.0 | (57)% | 99.5 | 113.4 | (12)% | |||||||||||
| APOKYN | 20.1 | 18.7 | 73.9 | 75.1 | (2)% | ||||||||||||
| Trokendi XR | 14.8 | 19.6 | (24)% | 63.2 | 94.3 | (33)% | |||||||||||
| Other(3) | 7.0 | 8.3 | (16)% | 29.0 | 31.3 | (7)% | |||||||||||
| Total net product sales | $ | 166.4 | $ | 156.0 | $ | 637.7 | $ | 573.9 | |||||||||
| Royalty, licensing and other revenues(4) | 7.8 | 8.3 | (6)% | 24.1 | 33.6 | (28)% | |||||||||||
| Total revenues | $ | 174.2 | $ | 164.3 | $ | 661.8 | $ | 607.5 | |||||||||
| Total revenues excluding Trokendi XR and Oxtellar XR net product sales (non-GAAP)(1) | $ | 146.2 | $ | 113.7 | $ | 499.1 | $ | 399.8 | |||||||||
- Total revenues were
$174.2 million and$661.8 million for the three and twelve months ended December 31, 2024, compared to$164.3 million and$607.5 million in the same periods in 2023, respectively.- Total net product sales were
$166.4 million and$637.7 million for the three and twelve months ended December 31, 2024, compared to$156.0 million and$573.9 million in the same periods in 2023, respectively. The increase in both periods was primarily due to increases in net sales of Qelbree and GOCOVRI, partially offset by the decline in net product sales of Trokendi XR and Oxtellar XR due to generic erosion. - Total revenues excluding Trokendi XR and Oxtellar XR net product sales (non-GAAP) increased
29% and25% for the three and twelve months ended December 31, 2024, compared to the same periods in 2023, respectively.
- Total net product sales were
Other Financial Highlights
- Operating earnings were
$21.4 million and$81.7 million for the three and twelve months ended December 31, 2024, compared to operating loss of$(1.0) million and$(5.3) million for the same periods in 2023, respectively. The positive increase in both periods was primarily due to an increase in total net product sales. Furthermore, the fourth quarter of 2023 included$20.2 million in intangible asset impairment charges, mainly related to XADAGO. - Adjusted operating earnings (non-GAAP) were
$48.3 million and$183.7 million for the three and twelve months ended December 31, 2024, compared to$47.1 million and$125.1 million for the same periods in 2023, respectively. - Net earnings and diluted earnings per share were
$15.3 million and$0.27 for the three months and$73.9 million and$1.32 for the twelve months ended December 31, 2024, respectively, compared to net earnings and diluted earnings per share of$1.2 million and$0.02 for the three months and$1.3 million and$0.02 for the twelve months ended December 31, 2023, respectively. - At December 31, 2024, cash, cash equivalents, and current and long-term marketable securities were approximately
$453.6 million compared to$271.5 million as of December 31, 2023. This increase was primarily due to cash generated from operations.
Full Year 2025 Financial Guidance
For the full year 2025, the Company is providing the financial guidance for total revenues and operating earnings (GAAP and Non-GAAP) as set forth below (dollars in millions):
| Current Guidance (as of February 25, 2025) | |
| Total revenues (includes approximately | |
| Combined R&D and SG&A expenses | |
| Operating earnings (loss) | |
| Adjusted operating earnings (non-GAAP)(1) |
Non-GAAP Financial Information
This press release contains financial measures that present financial information which do not comply with United States generally accepted accounting principles (GAAP). The non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, or superior to measures prepared in accordance with GAAP. Non-GAAP adjusted operating earnings on a historical and projected basis adjusts for non-cash share-based compensation expense, depreciation and amortization, intangible asset impairment charges and changes to fair value of contingent consideration, and for factors that are unusual, non-recurring or unpredictable, and excludes those costs, expenses, and other specified items presented in the reconciliation tables in this press release. In addition to non-GAAP adjusted operating earnings, we also present total revenues excluding net product sales of Trokendi XR (GAAP) and Oxtellar XR (GAAP), which is a non-GAAP measure and is calculated as total revenues (GAAP) less net product sales of Trokendi XR (GAAP) and Oxtellar XR (GAAP). Beginning in the year a product loses exclusivity due to generic entrants we generally do not expect net product sales of such products to constitute a significant part of our revenue in the future. We believe that the use of non-GAAP financial measures provides useful supplemental information to management, investors, analysts and others regarding the Company’s revenue and results of operations and assist management, investors, analysts, and others in understanding and evaluating our revenue growth and the performance of the business.
There are limitations associated with the use of non-GAAP financial measures and therefore comparability may be limited. These limitations include: non-GAAP financial measures that may not be entirely comparable to similarly titled measures used by other companies; these may not reflect all items of income and expense, as applicable, that affect our operations; there may be potential differences among calculation methodologies; these may differ from the non-GAAP information used by other companies, including peer companies. We mitigate these limitations by reconciling the non-GAAP financial measure to the most comparable GAAP financial measure. Investors are encouraged to review the reconciliation. The Company’s 2024 financial guidance is also being provided on both a GAAP and a non-GAAP basis.
| End Notes |
(1) See the section titled “Non-GAAP Financial Information” for information about this non-GAAP financial measure. A reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure is included at the end of this press release.
(2) IQVIA data restatement July 1, 2024.
(3) Includes net product sales of MYOBLOC®, XADAGO® and Osmolex ER®.
(4) Royalty, licensing, and other revenues include royalties on generic Trokendi XR, other licensed products and intellectual property.
(5) Includes net product sales and royalty, licensing, and other revenue.
(6) Reflects continued generic erosion of Trokendi XR and generic erosion of Oxtellar XR beginning in September 2024.
Conference Call Details
Supernus will host a conference call and webcast today, February 25, 2025, at 4:30 p.m. Eastern Time to discuss these results.
A live webcast will be available in the Events & Presentations section of the Company’s Investor Relations website www.supernus.com/investors.
Participants may also pre-register any time before the call here. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.
Following the live call, a replay will be available on the Company's Investor Relations website www.supernus.com/investors. The webcast will be available on the Company’s website for 60 days following the live call.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders.
For more information, please visit www.supernus.com.
Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company’s ability to sustain and increase its profitability; the Company’s ability to raise sufficient capital to fully implement its corporate strategy; the implementation of the Company’s corporate strategy; the Company’s future financial performance and projected expenditures; the Company’s ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries; the Company’s ability to increase its net revenue from its products and the products of its subsidiaries; the Company’s ability to commercialize its products and the products of its subsidiaries; the Company’s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies; the Company’s product research and development activities, including the timing and progress of the Company’s clinical trials, and projected expenditures; the Company’s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company’s product candidates; the Company’s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others; the Company’s expectations regarding federal, state and foreign regulatory requirements; the therapeutic benefits, effectiveness and safety of the Company’s product candidates; the accuracy of the Company’s estimates of the size and characteristics of the markets that may be addressed by its product candidates; the Company’s ability to increase its manufacturing capabilities for its products and product candidates; the Company’s projected markets and growth in markets; the Company’s product formulations and patient needs and potential funding sources; the Company’s staffing needs; and other risk factors set forth from time to time in the Company’s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.
Supernus Pharmaceuticals, Inc.
Consolidated Balance Sheets
(in thousands, except share and per share data)
| December | December | ||||||
| 2024 | 2023 | ||||||
| Assets | |||||||
| Current assets | |||||||
| Cash and cash equivalents | $ | 69,331 | $ | 75,054 | |||
| Marketable securities | 384,281 | 179,820 | |||||
| Accounts receivable, net | 142,077 | 144,155 | |||||
| Inventories, net | 54,293 | 77,408 | |||||
| Prepaid expenses and other current assets | 36,088 | 16,676 | |||||
| Total current assets | 686,070 | 493,113 | |||||
| Long-term marketable securities | — | 16,617 | |||||
| Property and equipment, net | 11,545 | 13,530 | |||||
| Intangible assets, net | 521,912 | 599,889 | |||||
| Goodwill | 117,019 | 117,019 | |||||
| Other assets | 31,527 | 37,505 | |||||
| Total assets | $ | 1,368,073 | $ | 1,277,673 | |||
| Liabilities and stockholders’ equity | |||||||
| Current liabilities | |||||||
| Accounts payable and accrued liabilities | $ | 76,352 | $ | 79,569 | |||
| Accrued product returns and rebates | 168,705 | 154,274 | |||||
| Contingent consideration, current portion | 47,340 | 52,070 | |||||
| Other current liabilities | — | 4,283 | |||||
| Total current liabilities | 292,397 | 290,196 | |||||
| Contingent consideration, long-term | — | 1,380 | |||||
| Operating lease liabilities, long-term | 27,382 | 33,196 | |||||
| Deferred income tax liabilities, net | 4,961 | 24,963 | |||||
| Other liabilities | 7,600 | 6,422 | |||||
| Total liabilities | 332,340 | 356,157 | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity | |||||||
| Common stock, | 56 | 55 | |||||
| Additional paid-in capital | 479,440 | 439,493 | |||||
| Accumulated other comprehensive loss, net of tax | (189) | (593) | |||||
| Retained earnings | 556,426 | 482,561 | |||||
| Total stockholders’ equity | 1,035,733 | 921,516 | |||||
| Total liabilities and stockholders’ equity | $ | 1,368,073 | $ | 1,277,673 | |||
Supernus Pharmaceuticals, Inc.
Consolidated Statements of Earnings
(in thousands, except share and per share data)
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||
| Revenues | ||||||||||||||
| Net product sales | $ | 166,395 | $ | 156,018 | $ | 637,696 | $ | 573,933 | ||||||
| Royalty, licensing and other revenues | 7,764 | 8,296 | 24,121 | 33,588 | ||||||||||
| Total revenues | 174,159 | 164,314 | 661,817 | 607,521 | ||||||||||
| Costs and expenses | ||||||||||||||
| Cost of goods sold(a) | 26,098 | 19,627 | 77,906 | 83,779 | ||||||||||
| Research and development | 28,647 | 23,347 | 108,796 | 91,593 | ||||||||||
| Selling, general and administrative | 79,409 | 81,282 | 321,582 | 336,361 | ||||||||||
| Amortization of intangible assets | 18,244 | 21,069 | 77,977 | 82,385 | ||||||||||
| Intangible asset impairment charges | — | 20,189 | — | 20,189 | ||||||||||
| Contingent consideration loss (gain) | 356 | (204) | (6,110) | (1,517) | ||||||||||
| Total costs and expenses | 152,754 | 165,310 | 580,151 | 612,790 | ||||||||||
| Operating earnings (loss) | 21,405 | (996) | 81,666 | (5,269) | ||||||||||
| Other income (expense) | ||||||||||||||
| Interest and other income, net | 4,977 | 1,986 | 16,204 | 10,453 | ||||||||||
| Interest expense | — | — | — | (2,415) | ||||||||||
| Total other income (expense), net | 4,977 | 1,986 | 16,204 | 8,038 | ||||||||||
| Earnings before income taxes | 26,382 | 990 | 97,870 | 2,769 | ||||||||||
| Income tax expense (benefit) | 11,054 | (185) | 24,005 | 1,453 | ||||||||||
| Net earnings | $ | 15,328 | $ | 1,175 | $ | 73,865 | $ | 1,316 | ||||||
| Earnings per share | ||||||||||||||
| Basic | $ | 0.28 | $ | 0.02 | $ | 1.34 | $ | 0.02 | ||||||
| Diluted | $ | 0.27 | $ | 0.02 | $ | 1.32 | $ | 0.02 | ||||||
| Weighted average shares outstanding | ||||||||||||||
| Basic | 55,465,403 | 54,647,835 | 55,100,063 | 54,536,281 | ||||||||||
| Diluted | 56,464,768 | 55,301,319 | 55,958,537 | 55,506,828 | ||||||||||
(a) Excludes amortization of intangible assets.
Supernus Pharmaceuticals, Inc.
Reconciliations of GAAP to Non-GAAP Financial Information
Reconciliation of GAAP Total revenues to Non-GAAP Total revenues excluding Trokendi XR and Oxtellar XR net product sales
An itemized reconciliation between total revenues on a GAAP basis and Total revenues excluding Trokendi XR and Oxtellar XR net product sales, a non-GAAP measure, is as follows (dollars in millions):
| Three Months Ended December 31, | Year Ended December 31, | ||||||||||||||||||||
| 2024 | 2023 | Change % | 2024 | 2023 | Change % | ||||||||||||||||
| Total revenues (GAAP)(1) | $ | 174.2 | $ | 164.3 | $ | 661.8 | $ | 607.5 | |||||||||||||
| Adjustments: | |||||||||||||||||||||
| Trokendi XR net product sales | (14.8) | (19.6) | (24)% | (63.2) | (94.3) | (33)% | |||||||||||||||
| Oxtellar XR net product sales | (13.2) | (31.0) | (57)% | (99.5) | (113.4) | (12)% | |||||||||||||||
| Total revenues excluding Trokendi XR and Oxtellar XR net product sales (non-GAAP)(1) | $ | 146.2 | $ | 113.7 | $ | 499.1 | $ | 399.8 | |||||||||||||
(1) Includes net product sales and royalty, licensing, and other revenues.
Reconciliation of GAAP Operating Earnings (Loss) to Non-GAAP Adjusted Operating Earnings
An itemized reconciliation between operating earnings (loss) on a GAAP basis and adjusted operating earnings on a non-GAAP basis is as follows (dollars in millions):
| Three Months Ended December 31, | Year Ended December 31, | |||||||||||||
| 2024 | 2023 | 2024 | 2023 | |||||||||||
| Operating earnings (loss) - As Reported (GAAP) | $ | 21.4 | $ | (1.0) | $ | 81.7 | (5.3) | |||||||
| Adjustments: | ||||||||||||||
| Amortization of intangible assets | 18.2 | 21.1 | 77.9 | 82.4 | ||||||||||
| Share-based compensation | 7.7 | 6.4 | 27.8 | 26.8 | ||||||||||
| Contingent consideration loss (gain) | 0.4 | (0.2) | (6.1) | (1.5) | ||||||||||
| Intangible assets impairment charges | — | 20.2 | — | 20.2 | ||||||||||
| Depreciation | 0.6 | 0.6 | 2.4 | 2.5 | ||||||||||
| Operating earnings - As Adjusted (non-GAAP) | $ | 48.3 | $ | 47.1 | $ | 183.7 | $ | 125.1 | ||||||
Non-GAAP adjusted operating earnings adjusts for non-cash items including amortization of intangible assets, share-based compensation expense, change in fair value of contingent consideration, intangible assets impairment charges, and depreciation.
Reconciliation of Full Year 2025 Financial Guidance - GAAP Operating Earnings (Loss) to Non-GAAP Adjusted Operating Earnings
An itemized reconciliation between projected operating earnings (loss) on a GAAP basis for the full year 2025 and projected adjusted operating earnings on a non-GAAP basis for the full year 2025 is as follows (dollars in millions):
| Current Guidance (as of February 25, 2025) | |
| Operating earnings (loss) - GAAP | |
| Adjustments: | |
| Amortization of intangible assets | |
| Share-based compensation | |
| Contingent consideration loss | |
| Depreciation | |
| Operating earnings - As Adjusted (non-GAAP) |
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
peter.vozzo@icrhealthcare.com
FAQ
What were Supernus Pharmaceuticals (SUPN) key revenue figures for 2024?
When will Supernus launch ONAPGO for Parkinson's disease?
How long is Qelbree patent protection extended for SUPN?
What is Supernus's revenue guidance for 2025?
How did Qelbree prescriptions perform in 2024?
